A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and
pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B
(Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV)
genotype
1-infected subjects who are either naive to treatment or who have previously failed treatment
(non-responders).